Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system
(2021) In Atherosclerosis 334. p.76-84- Abstract
Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with high-density lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1-phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review... (More)
Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with high-density lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1-phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1P-signaling may be beneficial to patients with cardiovascular and inflammatory diseases.
(Less)
- author
- Yao Mattisson, Ingrid LU and Christoffersen, Christina
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Apolipoprotein M, Cardiovascular disease, Endothelial dysfunction, Inflammation, Lipid metabolism, Sphingosine-1-phosphate
- in
- Atherosclerosis
- volume
- 334
- pages
- 9 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85114364006
- pmid:34482091
- ISSN
- 0021-9150
- DOI
- 10.1016/j.atherosclerosis.2021.08.039
- language
- English
- LU publication?
- yes
- id
- 3771679b-a405-4da1-9ea4-fd4faf2915cf
- date added to LUP
- 2021-10-11 14:46:22
- date last changed
- 2024-06-15 17:50:03
@article{3771679b-a405-4da1-9ea4-fd4faf2915cf,
abstract = {{<p>Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with high-density lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1-phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1P-signaling may be beneficial to patients with cardiovascular and inflammatory diseases.</p>}},
author = {{Yao Mattisson, Ingrid and Christoffersen, Christina}},
issn = {{0021-9150}},
keywords = {{Apolipoprotein M; Cardiovascular disease; Endothelial dysfunction; Inflammation; Lipid metabolism; Sphingosine-1-phosphate}},
language = {{eng}},
pages = {{76--84}},
publisher = {{Elsevier}},
series = {{Atherosclerosis}},
title = {{Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system}},
url = {{http://dx.doi.org/10.1016/j.atherosclerosis.2021.08.039}},
doi = {{10.1016/j.atherosclerosis.2021.08.039}},
volume = {{334}},
year = {{2021}},
}